Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Bert La Du

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Genes & Molecular Sequences

Amino Acid Sequence

Physiology

Phenotype

Phenomena

Living Beings

Rabbits

Procedures

Polymerase Chain Reaction

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
14
Billecke, Scott
13
Bartels, Cynthia
12
Draganov, Dragomir
11
Lockridge, Oksana
10
Sorenson, RC
9
Primo-Parmo, SL
7
Van Der Spek, Abraham
7
Bisgaier, Charles
7
Aviram, Michael
6
Hsu, C
5
Navab, Mohamad
4
Rosenblat, Mira
4
Teiber, John
4
Fogelman, Alan
4
Arpagaus, Martine

Sign-in to see all Coauthors

Publications

TOP 3
Teiber John F; Billecke Scott S; La Du Bert N; Draganov Dragomir I
Estrogen esters as substrates for human paraoxonases.
Draganov Dragomir I; Teiber John F; Speelman Audrey; Osawa Yoichi; Sunahara Roger; La Du Bert N
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
Teiber John F; Draganov Dragomir I; La Du Bert N
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Bert La Du (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Teiber John F; Billecke Scott S; La Du Bert N; Draganov Dragomir I
Estrogen esters as substrates for human paraoxonases.
Archives of biochemistry and biophysics 2007;461(1):24-9.
2005: Draganov Dragomir I; Teiber John F; Speelman Audrey; Osawa Yoichi; Sunahara Roger; La Du Bert N
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
Journal of lipid research 2005;46(6):1239-47.
2004: Teiber John F; Draganov Dragomir I; La Du Bert N
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH.
Journal of lipid research 2004;45(12):2260-8.
2004: Draganov D I; La Du B N
Pharmacogenetics of paraoxonases: a brief review.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(1):78-88.
2003: Teiber John F; Draganov Dragomir I; La Du Bert N
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3.
Biochemical pharmacology 2003;66(6):887-96.
2003: La Du Bert N
Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(8):1317-8.
2003: Rosenblat Mira; Draganov Dragomir; Watson Catherine E; Bisgaier Charles L; La Du Bert N; Aviram Michael
Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(3):468-74.
2003: Ahmed Zakaria; Babaei Saeid; Maguire Graham F; Draganov Dragomir; Kuksis Arnis; La Du Bert N; Connelly Philip W
Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine.
Cardiovascular research 2003;57(1):225-31.
2002: Satoh Tetsuo; Taylor Palmer; Bosron William F; Sanghani Sonal P; Hosokawa Masakiyo; La Du Bert N
Current progress on esterases: from molecular structure to function.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(5):488-93.
2002: Ahmed Zakaria; Ravandi Amir; Maguire Graham F; Emili Andrew; Draganov Dragomir; La Du Bert N; Kuksis Arnis; Connelly Philip W
Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite.
Biochemical and biophysical research communications 2002;290(1):391-6.
2001: Ahmed Z; Ravandi A; Maguire G F; Emili A; Draganov D; La Du B N; Kuksis A; Connelly P W
Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor.
The Journal of biological chemistry 2001;276(27):24473-81.
2001: La Du B N; Billecke S; Hsu C; Haley R W; Broomfield C A
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):566-9.
2001: Watson C E; Draganov D I; Billecke S S; Bisgaier C L; La Du B N
Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.
Pharmacogenetics 2001;11(2):123-34.
2000: Billecke S; Draganov D; Counsell R; Stetson P; Watson C; Hsu C; La Du B N
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1335-42.
2000: Draganov D I; Stetson P L; Watson C E; Billecke S S; La Du B N
Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.
The Journal of biological chemistry 2000;275(43):33435-42.
1999: Naguib M; Gomaa M; Samarkandi A H; Bevan D R; Akkielah A K; Watson C; Billecke S; La Du B N
Increased plasma cholinesterase activity and mivacurium resistance: report of a family.
Anesthesia and analgesia 1999;89(6):1579-82.
1999: Sorenson R C; Bisgaier C L; Aviram M; Hsu C; Billecke S; La Du B N
Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(9):2214-25.
1999: Haley R W; Billecke S; La Du B N
Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans.
Toxicology and applied pharmacology 1999;157(3):227-33.
1999: La Du B N; Furlong C E; Reiner E
Recommended nomenclature system for the paraoxonases.
Chemico-biological interactions 1999;119-120():599-601.
1999: La Du B N; Aviram M; Billecke S; Navab M; Primo-Parmo S; Sorenson R C; Standiford T J
On the physiological role(s) of the paraoxonases.
Chemico-biological interactions 1999;119-120():379-88.
1999: Billecke S S; Primo-Parmo S L; Dunlop C S; Doorn J A; La Du B N; Broomfield C A
Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.
Chemico-biological interactions 1999;119-120():251-6.
1999: Sorenson R C; Aviram M; Bisgaier C L; Billecke S; Hsu C; La Du B N
Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase.
Chemico-biological interactions 1999;119-120():243-9.
1999: Doorn J A; Sorenson R C; Billecke S S; Hsu C; La Du B N
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.
Chemico-biological interactions 1999;119-120():235-41.
1999: Aviram M; Rosenblat M; Billecke S; Erogul J; Sorenson R; Bisgaier C L; Newton R S; La Du B
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
Free radical biology & medicine 1999;26(7-8):892-904.
1998: Navab M; Hama S Y; Hough G P; Hedrick C C; Sorenson R; La Du B N; Kobashigawa J A; Fonarow G C; Berliner J A; Laks H; Fogelman A M
High density associated enzymes: their role in vascular biology.
Current opinion in lipidology 1998;9(5):449-56.
1998: Aviram M; Billecke S; Sorenson R; Bisgaier C; Newton R; Rosenblat M; Erogul J; Hsu C; Dunlop C; La Du B
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(10):1617-24.
1998: Kuo C L; La Du B N
Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(7):653-60.
1998: Aviram M; Rosenblat M; Bisgaier C L; Newton R S; Primo-Parmo S L; La Du B N
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
The Journal of clinical investigation 1998;101(8):1581-90.
1998: La Du B N
Are we ready to try to cure alkaptonuria?
American journal of human genetics 1998;62(4):765-7.
1997: Hallagan J B; La Du B N; Pariza M W; Putnam J M; Borzelleca J F
Assessment of cassia gum.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1997;35(6):625-32.
1997: Navab M; Hama-Levy S; Van Lenten B J; Fonarow G C; Cardinez C J; Castellani L W; Brennan M L; Lusis A J; Fogelman A M; La Du B N
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
The Journal of clinical investigation 1997;99(8):2005-19.
1997: Primo-Parmo S L; Lightstone H; La Du B N
Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase.
Pharmacogenetics 1997;7(1):27-34.
1996: Primo-Parmo S L; Sorenson R C; Teiber J; La Du B N
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.
Genomics 1996;33(3):498-507.
1996: Primo-Parmo S L; Bartels C F; Wiersema B; van der Spek A F; Innis J W; La Du B N
Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene.
American journal of human genetics 1996;58(1):52-64.
1995: Sorenson R C; Primo-Parmo S L; Camper S A; La Du B N
The genetic mapping and gene structure of mouse paraoxonase/arylesterase.
Genomics 1995;30(3):431-8.
1995: Watson A D; Berliner J A; Hama S Y; La Du B N; Faull K F; Fogelman A M; Navab M
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.
The Journal of clinical investigation 1995;96(6):2882-91.
1995: Van Lenten B J; Hama S Y; de Beer F C; Stafforini D M; McIntyre T M; Prescott S M; La Du B N; Fogelman A M; Navab M
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
The Journal of clinical investigation 1995;96(6):2758-67.
1995: Kuo C L; La Du B N
Comparison of purified human and rabbit serum paraoxonases.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(9):935-44.
1995: Sorenson R C; Primo-Parmo S L; Kuo C L; Adkins S; Lockridge O; La Du B N
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(16):7187-91.
1995: Greenberg C P; Primo-Parmo S L; Pantuck E J; la Du B N
Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods.
Anesthesia and analgesia 1995;81(2):419-21.
1993: La Du B N; Adkins S; Kuo C L; Lipsig D
Studies on human serum paraoxonase/arylesterase.
Chemico-biological interactions 1993;87(1-3):25-34.
1993: Nogueira C P; Evans D A; La Du B N
The paraoxonase polymorphism in a Saudi Arabian population.
Pharmacogenetics 1993;3(3):144-9.
1993: Adkins S; Gan K N; Mody M; La Du B N
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.
American journal of human genetics 1993;52(3):598-608.
1992: Nogueira C P; Bartels C F; McGuire M C; Adkins S; Lubrano T; Rubinstein H M; Lightstone H; Van der Spek A F; Lockridge O; La Du B N
Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase.
American journal of human genetics 1992;51(4):821-8.
1992: Jensen F S; Bartels C F; La Du B N
Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families.
Pharmacogenetics 1992;2(5):234-40.
1992: Bartels C F; Jensen F S; Lockridge O; van der Spek A F; Rubinstein H M; Lubrano T; La Du B N
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.
American journal of human genetics 1992;50(5):1086-103.
1992: Bartels C F; James K; La Du B N
DNA mutations associated with the human butyrylcholinesterase J-variant.
American journal of human genetics 1992;50(5):1104-14.
1992: Hajra A; Sorenson R C; La Du B N
Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes.
Pharmacogenetics 1992;2(2):78-88.
1991: Arpagaus M; Chatonnet A; Masson P; Newton M; Vaughan T A; Bartels C F; Nogueira C P; La Du B N; Lockridge O
Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates.
The Journal of biological chemistry 1991;266(11):6966-74.
1991: La Du B N; Bartels C F; Nogueira C P; Arpagaus M; Lockridge O
Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.
Cellular and molecular neurobiology 1991;11(1):79-89.
1991: La Du B N
Alcaptonuria and ochronotic arthritis.
Molecular biology & medicine 1991;8(1):31-8.
1991: Smolen A; Eckerson H W; Gan K N; Hailat N; La Du B N
Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(1):107-12.
1991: Gan K N; Smolen A; Eckerson H W; La Du B N
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(1):100-6.
1990: La Du B N; Bartels C F; Nogueira C P; Hajra A; Lightstone H; Van der Spek A; Lockridge O
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants.
Clinical biochemistry 1990;23(5):423-31.
1990: Bartels C F; van der Spek A F; La Du B N
Two polymorphisms in the non-coding regions of the BCHE gene.
Nucleic acids research 1990;18(20):6171.
1990: Nogueira C P; McGuire M C; Graeser C; Bartels C F; Arpagaus M; Van der Spek A F; Lightstone H; Lockridge O; La Du B N
Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG).
American journal of human genetics 1990;46(5):934-42.
1990: Arpagaus M; Kott M; Vatsis K P; Bartels C F; La Du B N; Lockridge O
Structure of the gene for human butyrylcholinesterase. Evidence for a single copy.
Biochemistry 1990;29(1):124-31.
1989: McGuire M C; Nogueira C P; Bartels C F; Lightstone H; Hajra A; Van der Spek A F; Lockridge O; La Du B N
Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):953-7.
1988: La Du B N
The human serum paraoxonase/arylesterase polymorphism.
American journal of human genetics 1988;43(3):227-9.
1987: McTiernan C; Adkins S; Chatonnet A; Vaughan T A; Bartels C F; Kott M; Rosenberry T L; La Du B N; Lockridge O
Brain cDNA clone for human cholinesterase.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(19):6682-6.
1987: Lockridge O; Adkins S; La Du B N
Location of disulfide bonds within the sequence of human serum cholinesterase.
The Journal of biological chemistry 1987;262(27):12945-52.
1986: La Du B N; Piko J I; Eckerson H W; Vincent-Viry M; Siest G
An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism.
Annales de biologie clinique 1986;44(4):369-72.
1986: Vincent-Viry M; La Du B N; Lepage L; Mikstacki T
[Distribution of different phenotypes of paraoxonase in a French population]
Annales de biologie clinique 1986;44(3):233-8.
1986: La Du B N; Adkins S; Bayoumi R A
Analysis of the serum paraoxonase/arylesterase polymorphism in some Sudanese families.
Progress in clinical and biological research 1986;214():87-98.
1985: Butler E G; Eckerson H W; La Du B N
Paraoxon hydrolysis vs. covalent binding in the elimination of paraoxon in the rabbit.
Drug metabolism and disposition: the biological fate of chemicals 1985;13(6):640-5.
1984: La Du B N; Eckerson H W
The polymorphic paraoxonase/arylesterase isozymes of human serum.
Federation proceedings 1984;43(8):2338-41.
1984: Eckerson H W; La Du B N
A mathematical model for evaluating the reaction of paraoxon with human serum cholinesterase and with polymorphic forms of paraoxonase.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(1):57-62.
1983: Eckerson H W; Wyte C M; La Du B N
The human serum paraoxonase/arylesterase polymorphism.
American journal of human genetics 1983;35(6):1126-38.
1983: Eckerson H W; Romson J; Wyte C; La Du B N
The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts.
American journal of human genetics 1983;35(2):214-27.
1983: Eckerson H W; Oseroff A; Lockridge O; La Du B N
Immunological comparison of the usual and atypical human serum cholinesterase phenotypes.
Biochemical genetics 1983;21(1-2):93-108.
1981: Valentino R J; Lockridge O; Eckerson H W; La Du B N
Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies.
Biochemical pharmacology 1981;30(12):1643-9.
1980: Lockridge O; Mottershaw-Jackson N; Eckerson H W; La Du B N
Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase.
The Journal of pharmacology and experimental therapeutics 1980;215(1):1-8.

Sign-in to see more